JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

AZN

81.69

-0.11%↓

Search

Eli Lilly and Co.

Închisă

SectorSănătate

726.38 -2.12

Rezumat

Modificarea prețului

24h

Curent

Minim

724

Maxim

731

Indicatori cheie

By Trading Economics

Venit

2.9B

5.7B

Vânzări

2.8B

16B

P/E

Medie Sector

47.85

35.733

EPS

6.31

Randament dividend

0.77

Marjă de profit

36.384

Angajați

47,000

EBITDA

3.3B

7.5B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+22.99% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.77%

3.13%

Următoarele câștiguri

30 oct. 2025

Data viitoare de dividende

10 sept. 2025

Următoarea dată ex-dividende

14 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-34B

657B

Deschiderea anterioară

728.5

Închiderea anterioară

726.38

Sentimentul știrilor

By Acuity

34%

66%

113 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 aug. 2025, 15:59 UTC

Principalele dinamici ale pieței

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7 aug. 2025, 11:36 UTC

Câștiguri

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

26 aug. 2025, 13:57 UTC

Câștiguri

These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, DJT, Talen Energy, Semtech, and More -- Barrons.com

26 aug. 2025, 11:37 UTC

Câștiguri

These Stocks Are Moving the Most Today: AT&T, EchoStar, AMD, Lilly, Interactive Brokers, Talen Energy, and More -- Barrons.com

12 aug. 2025, 22:15 UTC

Achiziții, Fuziuni, Preluări

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 aug. 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 aug. 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 aug. 2025, 16:20 UTC

Câștiguri

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 aug. 2025, 14:18 UTC

Market Talk
Câștiguri

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 aug. 2025, 13:54 UTC

Câștiguri

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 aug. 2025, 12:12 UTC

Câștiguri

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 aug. 2025, 11:58 UTC

Câștiguri

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7 aug. 2025, 11:32 UTC

Câștiguri

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug. 2025, 11:03 UTC

Câștiguri

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug. 2025, 10:49 UTC

Câștiguri

Eli Lilly 2Q Gross Margin 84.3% >LLY

7 aug. 2025, 10:48 UTC

Câștiguri

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7 aug. 2025, 10:47 UTC

Câștiguri

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7 aug. 2025, 10:46 UTC

Câștiguri

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7 aug. 2025, 10:46 UTC

Câștiguri

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7 aug. 2025, 10:46 UTC

Câștiguri

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7 aug. 2025, 10:45 UTC

Câștiguri

Eli Lilly 2Q Net $5.66B >LLY

7 aug. 2025, 10:45 UTC

Câștiguri

Eli Lilly 2Q Rev $15.56B >LLY

7 aug. 2025, 10:45 UTC

Câștiguri

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

7 aug. 2025, 10:41 UTC

Câștiguri

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 aug. 2025, 20:34 UTC

Câștiguri

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 aug. 2025, 08:45 UTC

Câștiguri

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

30 iul. 2025, 10:38 UTC

Market Talk

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 iul. 2025, 17:05 UTC

Câștiguri

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 iul. 2025, 16:55 UTC

Câștiguri

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 iul. 2025, 13:35 UTC

Câștiguri

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

22.99% sus

Prognoză pe 12 luni

Medie 913.69 USD  22.99%

Maxim 1,190 USD

Minim 700 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

16

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 884.54Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

113 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat